Vivos Therapeutics, Inc. (VVOS)

Vivos Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	17.44	15.03	13.8	16.02	16.89
Revenue Growth (YoY)	16.05%	8.91%	-13.87%	-5.10%	29.23%
Cost of Revenue	6.9	6.01	5.53	6.01	4.28
Gross Profit	10.54	9.02	8.27	10.02	12.6
Selling, General & Admin	29.13	19.61	24.95	34.38	31.34
Depreciation & Amortization Expenses	1.31	0.58	0.62	0.67	0.73
Other Operating Expenses	-	-	-	-	0.91
Total Operating Expenses	30.44	20.19	25.57	35.05	32.99
Operating Income	-19.89	-11.17	-17.3	-25.03	-20.38
Interest Expense	-	-	-	-	-0.01
Other Non-Operating Income (Expense)	-1.34	0.04	3.71	1.19	0.11
Total Non-Operating Income (Expense)	-1.34	0.04	3.71	1.19	0.09
Pretax Income	-21.23	-11.14	-13.58	-23.85	-20.29
Net Income	-21.17	-11.14	-13.58	-23.85	-20.29
Minority Interest in Earnings	-0.06	-	-	-	-
Net Income to Common	-21.17	-11.14	-13.58	-23.85	-20.29
Shares Outstanding (Basic)	10	10	1,219	921	849
Shares Outstanding (Diluted)	10	10	1,219	921	849
Shares Change (YoY)	-	-99.16%	32.46%	8.38%	164917.87%
EPS (Basic)	-2.07	-2.22	-11.14	-25.90	-23.88
EPS (Diluted)	-2.07	-2.22	-11.14	-25.90	-23.88
Shares Outstanding	9.29	5.89	1.83	0.92	0.92
Free Cash Flow	-17.6	-13.26	-12.75	-20.51	-18.13
Free Cash Flow Per Share	-1.71	-1.29	-0.01	-0.02	-0.02
Gross Margin	60.44%	60.00%	59.93%	62.52%	74.65%
Operating Margin	-114.05%	-74.32%	-125.32%	-156.21%	-120.71%
Profit Margin	-121.71%	-74.09%	-98.42%	-148.81%	-120.15%
FCF Margin	-100.92%	-88.21%	-92.38%	-128.00%	-107.38%
EBITDA	-18.59	-10.59	-16.68	-24.36	-19.65
EBITDA Margin	-106.55%	-70.45%	-120.83%	-152.03%	-116.37%
EBIT	-19.89	-11.17	-17.3	-25.03	-20.38
EBIT Margin	-114.05%	-74.32%	-125.32%	-156.21%	-120.71%

Updated Apr 15, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q